Table 1.
Baseline characteristics of the study population.
| Variables | Patients (n = 605) |
|---|---|
| Age (years) | 57 (50–64) |
| Male | 497 (82.1) |
| Cirrhosis | 511 (84.5) |
| Etiology | |
| HBV | 439 (72.6) |
| HCV | 85 (14.0) |
| Non-viral | 81 (13.4) |
| WBC (/mm3) | 5200 (4065–6500) |
| Platelets (×103/mm3) | 127 (82–177) |
| Child-Pugh score | 6 (5–7) |
| MELD-Na | 10 (8–13) |
| Serum AFP (ng/mL) | 110 (13–2150) |
| NLR | 2.0 (1.4–3.1) |
| PLR | 84.1 (63.1–125.2) |
| SII | 248.3 (140.9–445.3) |
| APRI | 1.3 (0.8–2.3) |
| FIB-4 | 4.4 (2.9–7.9) |
| Size of the largest tumor (cm) | 3.7 (2.0–7.6) |
| Tumor number | |
| Single | 276 (45.6) |
| Multiple | 329 (54.4) |
| Vascular invasion | 189 (31.2) |
| BCLC | |
| 0 | 43 (7.1) |
| A | 179 (29.6) |
| B | 92 (15.2) |
| C | 291 (48.1) |
Data are median (interquartile range) or number (%), unless otherwise indicated. AFP, alpha-fetoprotein; APRI, aspartate aminotransferase-to-platelet ratio index; BCLC, Barcelona Clinic liver cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD-Na, model for end-stage liver disease-sodium; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.